The healthcare sector has been a hotspot for investors seeking substantial returns. Over the past year, several companies have demonstrated remarkable growth, making them attractive picks for anyone looking to invest in the healthcare industry. Here’s a summary of the top performers:
Eli Lilly and Company (LLY)
Eli Lilly has outperformed its peers with an astounding 89.8% growth over the past year. This pharmaceutical giant has been at the forefront of innovation, particularly in the areas of diabetes and oncology, which has significantly boosted investor confidence and stock performance.
DaVita Inc. (DVA)
With a solid 57.02% growth, DaVita Inc. has proven to be a strong contender in the healthcare sector. Specializing in kidney care and dialysis services, DaVita has capitalized on the growing demand for specialized healthcare services, driving its impressive stock performance.
Boston Scientific Corporation (BSX)
Boston Scientific has seen a robust 45.95% growth over the past year. Known for its medical devices and innovative solutions, the company’s continuous advancements and successful product launches have kept it on a steady upward trajectory.
McKesson Corporation (MCK)
McKesson Corporation has enjoyed a 43.5% growth, reflecting its crucial role in the distribution of pharmaceuticals and medical supplies. McKesson’s expansive network and essential services in the healthcare supply chain have cemented its position as a reliable investment.
Cigna Corporation (CI)
Rounding out the list is Cigna Corporation, with a 33.8% growth over the past year. As a global health service company, Cigna’s diversified portfolio, including health insurance and related services, has contributed to its steady growth and market resilience.
The events that contributed to the 89.8% growth of Eli Lilly & Co over the past year include several key factors:
Strong Financial Results - Eli Lilly's stock price has benefited from consistently strong earnings and sales performance, often surpassing analysts' expectations.
Revenue Growth from Existing Drugs - Eli Lilly experienced revenue growth driven by higher demand for drugs like Jardiance, Verzenio, Taltz, Trulicity, and others.
New Drug Launches and Potential - Eli Lilly's growth has been fueled by its pipeline of new drug candidates, particularly in treating obesity and Alzheimer's. Drugs like Mounjaro, originally developed for diabetes and expected to be approved as a weight loss medication, and Donanemab, showing positive results in Alzheimer's treatment, have contributed significantly to Eli Lilly's growth.
Market Perception and Analyst Estimates - Positive revisions in analyst estimates and market perception towards Eli Lilly's business operations and profit generation have also played a role in the stock's growth.
Industry Performance - Eli Lilly's performance has stood out in the Large Cap Pharmaceuticals industry, despite the industry being in the bottom 17% echelons of all industries. Eli Lilly's growth has outperformed industry averages, contributing to its overall stock performance.
The 57.02% over the past year growth of Davita Inc. can be attributed to a combination of factors such as:
Strong Earnings Performance - DaVita Inc. has consistently reported robust earnings growth. In the third quarter of 2023, DaVita announced a net income increase to $247 million from $179 million in the previous quarter, with adjusted diluted earnings per share rising to $2.85 from $2.08. This strong financial performance has boosted investor confidence.
Operational Discipline and Strategic Investments - DaVita Inc. has focused on operating discipline and strategic investments to drive growth. DaVita has managed its outpatient clinic capacity and increased the proportion of home dialysis patients, which has led to higher revenue per treatment.
Growth in Revenue Per Treatment - Revenue per treatment has increased due to favorable changes in commercial and Medicare Advantage mix, as well as a net increase in average reimbursement rates. This growth in revenue per treatment has contributed to DaVita's overall financial performance.
Positive Normalized Non-Acquired Treatment Growth - DaVita Inc. has maintained positive normalized non-acquired treatment growth, indicating a steady increase in dialysis treatments. This growth has been consistent over the past year, with a year-over-year increase of 0.5% in the third quarter of 2023 and 0.4% in the first quarter of 2024.
Strong Cash Flow Generation - DaVita Inc. has maintained robust operating cash flow and free cash flow, which has provided financial flexibility and supported its growth initiatives.
DaVita Inc., founded in 1994 and headquartered in Denver, Colorado, provides kidney dialysis services for patients with chronic kidney failure or end-stage renal disease (ESRD). DaVita operates over 3,000 dialysis centers worldwide, offering outpatient, hospital inpatient, and home-based hemodialysis, along with comprehensive care services, disease management, vascular access services, clinical research programs, and physician services. DaVita also manages clinical laboratories for routine and ESRD-specific tests and provides administrative services to outpatient dialysis centers.
The events that contributed to the 45.95% over the past year growth of Boston Scientific Corporation include:
Strong Organic Growth Contribution from Single-Use Imaging and AXIOS Technologies - Boston Scientific reported strong organic growth from these technologies in the first quarter of 2024, which contributed to its overall growth.
Geographic Expansion - Boston Scientific's expansion into various geographies beyond the United States, particularly in emerging markets, has driven long-term revenue growth. Boston Scientific has seen robust growth in these regions, including in the Asia-Pacific and Latin America.
MedSurg Market Share Gain - Boston Scientific has consistently recovered its market share in the MedSurg segment, particularly in the Endoscopy business, which has seen strong worldwide demand for its gastrointestinal and pulmonary treatment options.
Strong Q1 Results - Boston Scientific reported a strong year-over-year improvement in organic sales, indicating a solid rebound in its legacy businesses across all geographic regions despite macroeconomic challenges.
Earnings Growth - Boston Scientific has consistently surpassed earnings estimates, with an average surprise of 7.5% over the past four quarters. Boston Scientific projects an estimated 13.2% earnings growth rate in 2024, compared to the industry's 12.6%.
Boston Scientific Corporation, founded in 1979 and headquartered in Marlborough, Massachusetts, specializes in developing, manufacturing, and marketing a wide range of medical devices globally. With operations divided into three segments—MedSurg, Rhythm and Neuro, and Cardiovascular—Boston Scientific offers innovative solutions for various interventional medical specialties. Its diverse portfolio includes devices for diagnosing and treating gastrointestinal, pulmonary, urological, and pelvic conditions, as well as solutions for managing heart rate and rhythm disorders, chronic pain, and structural heart therapies. Additionally, Boston Scientific provides interventional cardiology products for treating arterial and venous diseases, along with advanced technologies for cancer treatment.
The events that contributed to the 43.5% growth of McKesson Corporation over the past year include:
Rapid Adoption of GLP-1 Weight Loss Drugs - McKesson has seen significant growth in the prescription volume of GLP-1 weight loss drugs, which has driven revenue growth.
Increasing Demand for Specialty Pharmaceuticals - The demand for specialty pharmaceuticals, including cancer therapies, has been robust, contributing to the growth in the U.S. Pharmaceutical segment.
Expansion of Distribution Centers and AI Implementation - McKesson has expanded its distribution centers and implemented artificial intelligence (AI) in its services and products, enhancing operational efficiency and driving revenue growth.
Consistent Earnings Surprises - McKesson has consistently surprised the market with positive earnings, with an average surprise of 9.11% in the trailing four quarters.
Strong Performance in U.S. Pharmaceutical Segment - The U.S. Pharmaceutical segment has seen significant growth, driven by increased prescription volumes from specialty products, retail national account customers, and GLP-1 medications.
Prescription Technology Solutions Segment Growth - The Prescription Technology Solutions segment has experienced higher revenues due to seasonality and increased demand for access solutions, led by newly launched products.
Medical Surgical Solutions Segment Recovery - The Medical Surgical Solutions segment has reflected a sequential recovery in primary care visits and continued this trend in the fourth quarter, although patient volume and lower contributions from the U.S. government's COVID-19 vaccine program have acted as headwinds.
Strategic Focus on Oncology and Biopharma Services - McKesson's focus on oncology and biopharma services has driven growth through the expansion of its oncology network and strategic partnerships.
Return of Cash to Shareholders - McKesson has returned significant cash to shareholders through stock repurchases and dividends, enhancing investor confidence and supporting the stock price.
Operational Efficiency and Sustainability Efforts - McKesson's commitment to operational efficiency and sustainability has been recognized through various awards, further enhancing its reputation and investor confidence.
McKesson Corporation, founded in 1833 and headquartered in Irving, Texas, provides pharmaceuticals and medical supplies across four segments: U.S. Pharmaceutical, Prescription Technology Solutions, International, and Medical-Surgical Solutions. McKesson distributes a wide range of pharmaceutical drugs and healthcare products, offers practice management and clinical support, and provides solutions for life sciences companies. Additionally, it connects pharmacies, providers, payers, and biopharma for patient access and adherence solutions, and offers international drug distribution and specialty pharmacy services. McKesson also supplies medical-surgical products and logistics services to healthcare providers.
The events that contributed to the 33.8% growth of Cigna over the past year include:
Strategic Acquisitions and Collaborations - Cigna has been actively pursuing strategic acquisitions and collaborations, which have enhanced its growth prospects.
Rising Pharmacy Revenues - Cigna's pharmacy services have seen significant growth, with a projected 23.6% increase in 2024.
Growing Evernorth Segment - The Evernorth segment, which includes pharmacy benefits and specialty services, is expected to continue growing, driven by improved performance and new client acquisitions.
Consistent Earnings Surprises - Cigna has consistently beaten earnings estimates, with an average surprise of 2.9% over the last four quarters.
Positive Earnings ESP - Cigna's Earnings ESP, which compares the Most Accurate Estimate to the Zacks Consensus Estimate, is positive, indicating a strong likelihood of beating earnings expectations.
Zacks Rank and Style Scores - Cigna has a Zacks Rank of #3 (Hold) and Style Scores of A for Growth and VGM, indicating a strong growth potential and a high probability of success.
Undervaluation - The intrinsic value of Cigna stock is undervalued by 47%, providing a potential upside for investors.
Cigna Corporation, founded in 1792 and headquartered in Bloomfield, Connecticut, is a global provider of insurance and related services. It operates through segments including Health Services, Integrated Medical, International Markets, and Group Disability and Other, offering a wide range of health coverage, pharmacy benefits management, dental, vision, and supplemental insurance products. Cigna serves insured and self-insured clients, Medicare beneficiaries, multinational organizations, and individuals, distributing its products through various channels including insurance brokers, consultants, and private/public exchanges.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better trader.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
